Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?

Hepatology

Volumn 68, Issue 4, 2018, Pages 1621-1632

  Bajaj, Jasmohan S ^a   Moreau, Richard ^b,m   Kamath, Patrick S ^c   Vargas, Hugo E ^d   Arroyo, Vicente ^e   Reddy, K Rajender ^f   Szabo, Gyongyi ^g   Tandon, Puneeta ^h   Olson, Jody ⁱ   Karvellas, Constantine ^h   Gustot, Thierry ^j   Lai, Jennifer C ^k   Wong, Florence ^l  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INSERM   (France)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

^e Data Management Center   (Spain)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF MASSACHUSETTS   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY OF KANSAS   (United States)

^j ERASME HOSPITAL   (Belgium)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF TORONTO   (Canada)

^m BEAUJON HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE ON CHRONIC LIVER FAILURE; BRAIN DYSFUNCTION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE BURDEN; DISEASE SEVERITY; HEALTH CARE COST; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFECTION; INFLAMMATION; ISCHEMIA; KIDNEY DISEASE; LIVER TRANSPLANTATION; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT OUTCOME; ASIA; CAUSE OF DEATH; COMPLICATION; EUROPE; FEMALE; GRAFT REJECTION; LIVER CIRRHOSIS; MALE; MORTALITY; NORTH AMERICA; ORGAN DYSFUNCTION SCORE; PROCEDURES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ACUTE-ON-CHRONIC LIVER FAILURE; ASIA; CAUSE OF DEATH; EUROPE; FEMALE; GRAFT REJECTION; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NORTH AMERICA; ORGAN DYSFUNCTION SCORES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85049563516     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.30056     Document Type: Review

References (68)

1. Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep 2013;15:308.
2. Arroyo V, Moreau R, Kamath PS, Jalan R, Gines P, Nevens F, et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016;2:16041.
3. Asrani SK, Simonetto DA, Kamath PS. Acute-on-chronic liver failure. Clin Gastroenterol Hepatol 2015;13:2128-2139.
4. Jalan R, Pavesi M, Saliba F, Amoros A, Fernandez J, Holland-Fischer P, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. JHepatol 2015;62:831-840.
5. Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014;147:4-10.
6. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014;60:250-256.
7. Kim TY, Song DS, Kim HY, Sinn DH, Yoon EL, Kim CW, et al. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition. PLoS One 2016;11:e0146745.
8. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-1437.
9. Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 2016;64:2165-2172.
10. Moreau R, Jalan R, Arroyo V. Acute-on-chronic liver failure: recent concepts. JClin Exp Hepatol 2015;5:81-85.
11. O'Leary JG, Reddy KR, Garcia-Tsao G, Biggins SW, Wong F, Fallon MB, et al. NACSELD Acute-on-Chronic Liver Failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 2018; doi:10.1002/hep.29773. [Epub ahead of print]
12. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009;3:269-282.
13. Claria J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249-1264.
14. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. JHepatol 2015;63:1272-1284.
15. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015;16:343-353.
16. Szabo G, Saha B. Alcohol's effect on host defense. Alcohol Res 2015;37:159-170.
17. Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One 2014;9:e96864.
18. Szabo G, Petrasek J. Gut–liver axis and sterile signals in the development of alcoholic liver disease. Alcohol Alcohol 2017;52:414-424.
19. Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016;64:955-965.
20. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. JClin Invest 2012;122:3476-3489.
21. Fernandez J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2017; doi: 10.1136/gutjnl-2017-314240. [Epub ahead of print]
22. Lee MN, Ye C, Villani AC, Raj T, Li W, Eisenhaure TM, et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 2014;343:1246980.
23. Alcaraz-Quiles J, Titos E, Casulleras M, Pavesi M, Lopez-Vicario C, Rius B, et al. Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. Hepatology 2017;65:202-216.
24. Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease. JBiol Chem 2011;286:1436-1444.
25. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) experience. Hepatology 2012;56:2328-2335.
26. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. JHepatol 2014;61:1385-1396.
27. Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 2015;148:603-615.
28. 2 . Nat Med 2014;20:518-523.
29. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012;335:936-941.
30. Figueiredo N, Chora A, Raquel H, Pejanovic N, Pereira P, Hartleben B, et al. Anthracyclines induce DNA damage response–mediated protection against severe sepsis. Immunity 2013;39:874-884.
31. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. JHepatol 2014;60:940-947.
32. Szabo G. Gut–liver axis in alcoholic liver disease. Gastroenterology 2015;148:30-36.
33. Okabe Y, Medzhitov R. Tissue biology perspective on macrophages. Nat Immunol 2016;17:9-17.
34. Rabe C, Schmitz V, Paashaus M, Musch A, Zickermann H, Dumoulin FL, et al. Does intubation really equal death in cirrhotic patients? Factors influencing outcome in patients with liver cirrhosis requiring mechanical ventilation. Intensive Care Med 2004;30:1564-1571.
35. Plataki M, Hubmayr RD. The physical basis of ventilator-induced lung injury. Expert Rev Respir Med 2010;4:373-385.
36. Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
37. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243-252.
38. Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013;167:1101-1108.
39. Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. JHepatol 2016;64:717-735.
40. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015;64:531-537.
41. Angeli P, Rodriguez E, Piano S, Ariza X, Morando F, Sola E, et al. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut 2015;64:1616-1622.
42. Maiwall R, Kumar S, Chandel SS, Kumar G, Rastogi A, Bihari C, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis. Hepatol Int 2015;9:627-639.
43. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
44. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. JClin Exp Hepatol 2014;4:302-311.
45. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. JHepatol 2011;55:315-321.
46. Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015;62:567-574.
47. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). JHepatol 2014;60:275-281.
48. Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol 2017;15:565-574.
49. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. JHepatol 2004;40:247-254.
50. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-735.
51. Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013;57:2448-2457.
52. Reddy KR, O'Leary JG, Kamath PS, Fallon MB, Biggins SW, Wong F, et al. High risk of delisting or death in liver transplant candidates following infections: results from the North American Consortium for the Study of End-Stage Liver Disease. Liver Transpl 2015;21:881-888.
53. Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016;64:200-208.
54. Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Biggins SW, et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am J Gastroenterol 2018;113:556-563.
55. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46:1853-1862.
56. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153-1162.
57. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782-789.
58. Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. JHepatol 2017;67:708-715.
59. Finkenstedt A, Nachbaur K, Zoller H, Joannidis M, Pratschke J, Graziadei IW, et al. Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl 2013;19:879-886.
60. Umgelter A, Lange K, Kornberg A, Buchler P, Friess H, Schmid RM. Orthotopic liver transplantation in critically ill cirrhotic patients with multi-organ failure: a single-center experience. Transplant Proc 2011;43:3762-3768.
61. Levesque E, Winter A, Noorah Z, Daures JP, Landais P, Feray C, et al. Impact of acute-on-chronic liver failure on 90-day mortality following a first liver transplantation. Liver Int 2017;37:684-693.
62. Bittermann T, Makar G, Goldberg DS. Early post-transplant survival: interaction of MELD score and hospitalization status. JHepatol 2015;63:601-608.
63. Bahirwani R, Shaked O, Bewtra M, Forde K, Reddy KR. Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes. Transplantation 2011;92:952-957.
64. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. JGerontol A Biol Sci Med Sci 2001;56:M146-M156.
65. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014;14:1870-1879.
66. Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale. Am J Gastroenterol 2016;111:1759-1767.
67. Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017;66:564-574.
68. Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: “too well for transplant, too sick for life.” JAMA 2006;295:2168-2176.